Skip to main content

Table 2 Characteristics of Hizentra® administration with Q1W and Q2W dosage regimens

From: Pediatric subset of primary immunodeficiency patients treated with SCIG: post hoc analysis of SHIFT and IBIS pooled data

  Q1W (N = 15) Q2W (N = 13) Difference (90% CI)
Dosage/infusion (g) 4.3 ± 1.2 (4; 3.5–6) 6.7 ± 2.8 (8; 4.5–8) 2.18 (0.88–3.48)
Dosing interval (days) 7.8 ± 2.3 (7; 7–7) 14.9 ± 0.6 (15; 15–15) 6.73 (5.40–8.07)
Monthly dose (g) 18.0 ± 8.8 (16; 12–24) 13.7 ± 5.8 (16; 10–17) − 2.04 (− 8.30 to 4.23)
Number of infusion sites in parallel 1.7 ± 0.5 (2; 1–2) 1.9 ± 0.3 (2; 2–2) 0.38 (− 0.02 to 0.79)
Infusion length (h) n.a. 1.6 ± 0.5 (1.5; 1.2–2) n.a.
Cumulative infusion flow (mL/h) 8.5a 24.4 ± 12.2 (23; 18–26) n.a.
Pump (n.) n.a. 1.1 ± 0.3 (1; 1–1) n.a.
Serum IgG trough levels with Hizentra® (g/L) 8.4 ± 1.4 (8.1; 7.2–9.6) 8.5 ± 1.8 (8.4; 7.2–9.8) 0.28 (− 0.51–1.07)
  1. Data are reported as the mean ± standard deviation (median; interquartile range)
  2. n.a. non available, Q1W weekly administration, i.e., data from the SHIFT study, Q2W biweekly administration, i.e., data from the IBIS study
  3. aData available for only 1 subject who was administered therapy at 1 infusion site